We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Research Lab to Develop World’s First Neural Device to Restore Memory

By LabMedica International staff writers
Posted on 04 Aug 2014
Print article
Image: Lawrence Livermore National Laboratory (LLNL) will develop an implantable neural device with the ability to record and stimulate neurons within the brain to help restore memory (Photo courtesy of DOE/Lawrence Livermore National Laboratory).
Image: Lawrence Livermore National Laboratory (LLNL) will develop an implantable neural device with the ability to record and stimulate neurons within the brain to help restore memory (Photo courtesy of DOE/Lawrence Livermore National Laboratory).
A USD 2.5 million grant has been awarded to a US research lab to develop an implantable neural device with the ability to record and stimulate neurons within the brain to help restore memory.

The US Department of Defense’s Defense Advanced Research Projects Agency (DARPA) awarded the grant to Lawrence Livermore National Laboratory (LLNL; Livermore, CA, USA). The research builds on the knowledge that memory is a process in which neurons in specific regions of the brain encode information, store it, and retrieve it. Specific types of disorders and injuries, including traumatic brain injury (TBI), Alzheimer’s disease, and epilepsy, disrupt this process and cause memory loss. TBI, specifically, has affected 270,000 military service members since 2000.

The objective of LLNL’s research initiated by LLNL’s Neural Technology group and undertaken in collaboration with the University of California, Los Angeles (UCLA; USA) and Medtronic (Minneapolis, MN, USA) is to develop a device that uses real-time recording and closed-loop stimulation of neural tissues to bridge gaps in the injured brain and restore individuals’ ability to form new memories and access previously formed ones.

The research is funded by DARPA’s Restoring Active Memory (RAM) program. Specifically, the neural technology group are trying to develop a neuromodulation system, an advanced electronics system to modulate neurons, which will investigate areas of the brain associated with memory to understand how new memories are formed. The device will be developed at LLNL’s Center for Bioengineering.

“Currently, there is no effective treatment for memory loss resulting from conditions like TBI,” said LLNL’s project leader Dr. Satinderpall Pannu, director of the LLNL’s Center for Bioengineering, a unique facility dedicated to fabricating biocompatible neural interfaces. “This is a tremendous opportunity from DARPA to leverage Lawrence Livermore’s advanced capabilities to develop cutting-edge medical devices that will change the health care landscape.”

LLNL engineers will devise a miniature, wireless and chronically implantable neural device that will incorporate both single neuron and local field potential recordings into a closed-loop system to implant into TBI patients’ brains. The device implanted into the entorhinal cortex and hippocampus will allow for stimulation and recording from 64 channels located on two high-density electrode arrays. The entorhinal cortex and hippocampus are brain regions associated with memory.

The arrays will connect to an implantable electronics bundle capable of wireless data and power telemetry. An external electronic system worn around the ear will store digital information associated with memory storage and retrieval and provide power telemetry to the implantable package using a custom radiofrequency (RF) coil system.

The device’s electrodes will be integrated with electronics using advanced LLNL integration and 3D packaging technologies, and are designed to last throughout the duration of treatment. The microelectrodes that are the heart of this device are embedded in a biocompatible, flexible polymer. Using the Center for Bioengineering’s capabilities, Dr. Pannu and his team of engineers have achieved 25 patents and many publications during the last 10 years. The team's goal is to build the new prototype device for clinical testing by 2017.

Lawrence Livermore’s collaborators, UCLA and Medtronic, will focus on conducting clinical trials and creating parts and components, respectively. “The RAM program poses a formidable challenge reaching across multiple disciplines from basic brain research to medicine, computing and engineering,” said Itzhak Fried, lead investigator for the UCLA on this project and professor of neurosurgery and psychiatry and biobehavioral sciences at the David Geffen School of Medicine at UCLA and the Semel Institute for Neuroscience and Human Behavior. “But at the end of the day, it is the suffering individual, whether an injured member of the armed forces or a patient with Alzheimer’s disease, who is at the center of our thoughts and efforts.”

LLNL’s work on the Restoring Active Memory program supports President Obama’s Brain Research through Advancing Innovative Neurotechnologies (BRAIN) initiative. “Our years of experience developing implantable microdevices, through projects funded by the Department of Energy [DOE], prepared us to respond to DARPA’s challenge,” said Lawrence Livermore engineer Kedar Shah, a project leader in the neural technology group.

Related Links:

Lawrence Livermore National Laboratory
University of California, Los Angeles 
Medtronic


Gold Member
Troponin T QC
Troponin T Quality Control
Unit-Dose Packaging solution
HLX
New
Silver Member
Static Concentrator
BJP 10
New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Schematic overview of maternal biomarker discovery using cell-free RNA during pregnancy (Photo courtesy of Circulation Research (2024). DOI: 10.1161/CIRCRESAHA.124.325024)

Maternal Blood Test Identifies Congenital Heart Diseases in Fetus

Each year, around 1,000 children are born with a single ventricle heart defect (SVHD), a condition where one of the heart's lower chambers is underdeveloped, too small, or missing a valve.... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.